MA
SRPT icon

Montag & Associates’s Sarepta Therapeutics SRPT Stock Holding History

Montag & Associates’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-245
Closed -$4.19K – 1151
2025
Q2 		$4.19K Hold
245
– – ﹤0.01% 812
2025
Q1 		$15.6K Hold
245
– – ﹤0.01% 740
2024
Q4 		$29.8K Hold
245
– – ﹤0.01% 673
2024
Q3 		$30.6K Hold
245
– – ﹤0.01% 683
2024
Q2 		$38.7K Hold
245
– – ﹤0.01% 631
2024
Q1 		$31.7K Hold
245
– – ﹤0.01% 647
2023
Q4 		$23.6K Hold
245
– – ﹤0.01% 677
2023
Q3 		$29.7K Buy
+245
New +$27.7K ﹤0.01% 618

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Montag & Associates's SRPT Position: Q3 2025 in Review

Montag & Associates sold out of Sarepta Therapeutics (SRPT) in Q3 2025, closing a stake of 245 shares — an estimated $4.19K sold.

Montag & Associates first reported a position in SRPT in Q3 2023 and held it in 8 quarters. The position peaked at $38.7K in Q2 2024. 319 funds tracked by Wall St. Rank hold SRPT as of Q3 2025.

  • Montag & Associates reported no remaining Sarepta Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Montag & Associates sold 245 Sarepta Therapeutics shares in Q3 2025, an estimated $4.19K.
  • Montag & Associates first reported a position in Sarepta Therapeutics in Q3 2023 and held it in 8 quarters.
  • Montag & Associates's Sarepta Therapeutics position peaked at $38.7K in Q2 2024.
  • 319 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2025.

Based on Montag & Associates's 13F filing for Q3 2025, filed 12 Nov 2025.